Gilead's cell therapy head Christi Shaw leaving next month - Fierce Pharma
Feb 17, 2023 · When Christi Shaw joined Gilead Sciences's CAR-T outfit Kite Pharma back in 2019, the company had one approved cell therapy chipping in modestly toward overall growth. Now, after more than...
Christi Shaw to Depart Gilead and Kite Leadership End of Q1 - Kite Pharma
Feb 17, 2023 · “Under Christi’s leadership, Kite has become a global leader in cell therapy. Now, with an outstanding team in place, multiple approved indications and a growing pipeline, Kite is set to build on this positive momentum so it can help an …
Christi Shaw - Family Reach - LinkedIn
Christi Shaw has built a highly coordinated, patient-focused team at Kite united around the mission to cure cancer, which has led to a period of explosive growth for the company.
- 500+ connections
- Location: Family Reach
Gilead’s Shaw to step down from role running cell therapy unit
Feb 17, 2023 · Gilead’s Shaw to step down from role running cell therapy unit Shaw, who joined Gilead in 2019 from Eli Lilly, helped build Kite into a leading producer of cell therapies, convincing Wall Street skeptics in the process.
Kite Pharma’s Christi Shaw on the story behind her drive
Christi Shaw, former CEO, Kite Pharma, shares her thoughts on improving access to cell therapies and her motivations for working in oncology
Christi Shaw, Former CEO of Kite, a Gilead Company ... - Cellares
Mar 26, 2024 · Ms. Shaw is a life sciences leader and advocate for patients with more than 30 years of pharmaceutical industry experience across a broad range of therapeutic areas.
Christi Shaw, CEO of Gilead's Kite Pharmaceuticals, to depart - STAT
Feb 17, 2023 · C hristi Shaw, the CEO of Gilead’s Kite Pharmaceuticals cell therapy unit, is leaving the company, Gilead said Friday in a statement. Shaw, who took the Kite role in July 2019, had...
Gilead taps Roche exec to fly Kite—Chutes & Ladders - Fierce …
May 19, 2023 · Gilead Sciences has landed a new leader for cell-therapy-focused subsidiary Kite Pharma, naming Cindy Perettie as executive vice president of the company. Her appointment comes three months...
BRIEF—Christi Shaw to quit as CEO of Kite | The Pharmaletter
Feb 20, 2023 · During Ms Shaw’s time leading Kite, the company has gone from treating a few hundred patients with CAR T-cell therapy to now nearly 13,000 globally with two products and five regulatory indications, including approvals in over 20 countries around the world, Gilead noted.
Roche oncology veteran Cindy Perettie to fly Gilead's CAR-T unit Kite
May 17, 2023 · Gilead has hired Cindy Perettie to take over its cell therapy subsidiary Kite Pharma. Perettie replaces Christi Shaw, who served for four years.
- Some results have been removed